Robert E Johnson is a notable inventor based in Collegeville, PA (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of anti-inflammatory agents. With a total of three patents to his name, Johnson's work has the potential to impact the treatment of various chronic inflammatory disorders.

Latest Patents

Johnson's latest patents include innovative pharmaceutical methods for the use of 5-substituted and 5,5-disubstituted-3,4-dihydroxy-2(5H)-furanones. These inventions focus on synthetic methods for producing both optically active and racemic forms of these compounds. The compounds are designed to act as mixed inhibitors of lipid peroxidation, 5-lipoxygenase, cyclooxygenase-1, and cyclooxygenase-2. Furthermore, they are intended for use in treating chronic inflammatory disorders such as asthma, rheumatoid arthritis, inflammatory bowel disease, atherosclerosis, acute respiratory distress syndrome, and central nervous system disorders like Alzheimer's and Parkinson's disease.

Career Highlights

Johnson is currently associated with Oxis International, Inc., where he continues to advance his research and development efforts. His work has garnered attention for its potential applications in the pharmaceutical industry, particularly in the realm of anti-inflammatory treatments.

Collaborations

Some of Johnson's notable coworkers include Allen T Hopper and John A Ziemniak, who have collaborated with him on various projects within the company.

Conclusion

Robert E Johnson's innovative contributions to pharmaceutical methods highlight his commitment to addressing chronic inflammatory disorders. His patents reflect a significant advancement in the field, showcasing the potential for improved treatments in the future.